LENZ Therapeutics faces mounting cash burn, imminent dilution risk, and severe operational cuts, with no R&D pipeline. I rate LENZ stock as Sell. Read my analysis.
Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.
Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.